On January 10th, Boston Scientific announced that it had recently signed the final agreement for the acquisition of Axonics, Inc. The acquisition price is $71 per share, traded in cash, with an equity value of approximately $3.7 billion and a corporate value of approximately $3.4 billion. Axonics is a publicly listed medical technology company primarily dedicated to developing and selling new products for the treatment of bladder and intestinal dysfunction.